scispace - formally typeset
J

Jing Yang

Researcher at University of Texas MD Anderson Cancer Center

Publications -  80
Citations -  3576

Jing Yang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Multiple myeloma & Immunotherapy. The author has an hindex of 32, co-authored 76 publications receiving 3018 citations. Previous affiliations of Jing Yang include Peking Union Medical College & Houston Methodist Hospital.

Papers
More filters
Journal ArticleDOI

Th9 cells promote antitumor immune responses in vivo

TL;DR: The data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell-based cancer immunotherapy may be a promising therapeutic approach.
Journal ArticleDOI

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosis

TL;DR: The effects of macrophages (Mvarphis), a type of stromal cells, on myeloma cell survival and response to chemotherapy are examined and it is shown that Mvarphi, in particular tumor-associated M varphi, is a protector of myelomas cells.
Journal ArticleDOI

Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4 + and CD8 + T cells

TL;DR: Findings indicate that OCs can function as APCs and activate both CD4+ and CD8+ T cells in an MHC-restricted fashion, which provides new insight into the effect of OCs on the immune system and may help develop novel strategies for treating diseases, which affect both the bone and immune systems.
Journal ArticleDOI

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

TL;DR: This study shows that PSGL-1 (P-selectin glycoprotein ligand-1)/selectins and ICAM-1/CD18 played an important role in macrophage-mediated myeloma cell drug resistance, and provides novel targets for improving the efficacy of chemotherapy in patients.
Journal ArticleDOI

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

TL;DR: Results indicate that these T cells were potent cytotoxic T cells and recognized DKK1 peptides naturally presented by myeloma cells in the context of HLA-A*0201 molecules.